Merck & Co., Inc. (NYSE:MRK) is one of the 10 Safest Dividend Stocks to Buy Right Now.
On May 22, 2026, Merck & Co., Inc. (NYSE:MRK) completed a $6 billion underwritten public offering of senior notes across multiple tranches
The issuance carried out under an existing 2010 indenture with U.S. Bank Trust National Association spans maturities from 2028 to 2056. The offering consists of $500 million in floating-rate notes due 2028, alongside six fixed-rate tranches totaling $5.5 billion with coupons ranging between 4.300% and 5.850%.
The company has spread the maturities over a wide horizon, thereby successfully diversifying its liability profile and securing long-dated capital to fund ongoing corporate needs. In another development, on the same day, Merck & Co., Inc. (NYSE:MRK) announced that the EMA’s CHMP recommended approval of Keytruda combined with Padcev as a perioperative treatment for adults with resectable muscle-invasive bladder cancer ineligible for cisplatin chemotherapy. Based on the Phase 3 KEYNOTE-905 trial, the regimen reduced the risk of event-free survival events by 60% and death by 50% compared to surgery alone.